

ANSWER TO REVIEWERS

Florence November 12th, 2015

Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: 23092-edited revised.doc).

Title: Update on immunoglobulin a nephropathy. Part II: clinical, diagnostic and therapeutical aspects

Author: Maurizio Salvadori, Giuseppina Rosso

Name of Journal: *World Journal of Nephrology*

ESPS Manuscript NO: 23092

The manuscript has been improved according to the suggestions of the science editor and the reviewers:

1 Format has been updated, in particular:

- a) The English wording as been improved. The manuscript has been sent to American Journal Expert (certificate enclosed number 1978-AC1F-261A-635C-471B). The English modifications now appear in green color.
- b) A conflict of interest pdf file signed by both authors is enclosed.
- c) An audio core tip file is enclosed.
- d) All the references cited are on PubMed. The clinical trials may be found at: clinicaltrials.gov with the identification number provided. In addition a copy of these trials is enclosed

2 Revision has been made according to the suggestions of the reviewer

(1) Reviewer n° 00503334

- a) The English wording has been modified after sending the manuscript to: American Journal Expert (certificate enclosed). The modification appear now in green color.

(2) Reviewer n° 00503282

Thank you for your comments, which have been taken in consideration, improving the manuscript.

- a) The English wording has been modified after sending the manuscript to: American Journal Expert (certificate enclosed). The modification appear now in green color.
- b) Abbreviations have been modified as suggested.
- c) References full stops are now on the main line
- d) The new key words have been taken by MeSH
- e) Some of the references suggested have been added, and the manuscript modifies. Please find in red color the modifications

3 Reviewer n° 00503298

Thank you for your comments related to your specific experience in this topic

a) Abstract

The repeated phrases have been avoided. The suggested phrase on the discussion about therapies has been added. Please find all modifications in red color.

- b) Introduction
The IgAN abbreviation modification has been performed
We added the IgAN with AKI due to erythrocyte casts and with a good prognosis
- c) Research methodology
This short chapter has been rewritten. The word careful may be misleading and has been cancelled. Clearly we would only make an up to date on the IgAN and we did not had the ambition to be as scientific as the Cochrane Library, neither we would like to perform a guideline.
We started from the most recent papers (last three years) on the topic. Overall the selected papers were 40, excluding abstracts and RCTs. Then we went backward in the IgAN story and many other papers have been added. For the non immunological treatment of IgAN and for the immunological treatment, we found two recent Cochrane meta-analyses that have been properly cited. Obviously the more than one hundred references of these papers have not been reported. Concerning the trials we reported only those that actually are enrolling patients, thus selecting 15 RCT out of 68 whose we were not able to have any notice. The only exception has been made for the STOP-IgAN trial because the preliminary results have been recently reported in London. Please find the whole chapter rewritten in red.
- d) Diagnosis and prognosis
Comments on the limitations of the Oxford classification and of the problem of crescents have been made as suggested
- e) Biological marker
The four hits theory has been now explained
- f) Clinical markers
IgAN with AKI due to tubular necrosis and good prognosis has been added
- g) Leflunomide treatment has been reported as well as the relative references

3 References and typesetting were corrected

Thank you again for publishing our manuscript in the *World Journal of Nephrology*.

Sincerely yours,



Maurizio Salvadori, Department of Renal Transplantation and Renal Diseases, Careggi
University Hospital, 50139 Florence, Italy

